Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 8 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2
7(77.8%)
Phase 1
2(22.2%)
9Total
Phase 2(7)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials
NCT03776643Phase 2Completed

Safety and Efficacy of Low-dose IL-2 in Birch Pollen Allergy

Role: collaborator

NCT03970954Phase 1Completed

Low-dose Interleukin-2 in Women With Unexplained Miscarriages

Role: collaborator

NCT05153070Phase 2Recruiting

Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 Diabetes

Role: collaborator

NCT02411253Phase 2Completed

Low-dose rhIL-2 in Patients With Recently-diagnosed Type 1 Diabetes

Role: collaborator

NCT04133233Phase 2Completed

Low Dose IL-2 Therapy in Patients With a Depressive Episode in the Course of a Bipolar Disorder

Role: collaborator

NCT03837093Phase 1Completed

Low-dose IL-2 to the Kinetics of Regulatory T-cell in Healthy Volunteers

Role: collaborator

NCT04357444Phase 2Completed

Low Dose of IL-2 In Acute Respiratory DistrEss Syndrome Related to COVID-19

Role: collaborator

NCT01988506Phase 2Completed

Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases

Role: collaborator

NCT02955615Phase 2Completed

ILT-101 in Patients With Active Moderate to Severe Systemic Lupus Erythematosus (SLE)

Role: lead

All 9 trials loaded